|BBL1010||Dopamine D2 Receptor||Schizophrenia||Preclinical|
BBL1010 is BetaBlue's lead compound and is being developed as a therapeutic to treat schizophrenia.
Schizophrenia is a devastating psychiatric disorder affecting 1% - 2% of the global human population. Some symptoms can be alleviated existing antipsychotic drugs, however, there exists a significant margin for improvement in their clinical efficacy because of high incidence of side-effects thought to be associated with their non-specific off-target activity. BetaBlue is developing therapeutics for use in schizophrenia that promise unprecedented specificity for dopamine receptor pathways in appropriate regions of the brain.
The differentiation of BetaBlue’s lead antipsychotic for schizophrenia, BBL1010, is based upon a solid scientific understanding of the importance of strategically stabilizing dopamine signaling in the brain cortex and striatum. This is thought to be possible through the ability of BBL1010 to influence the β-arrestin and G-protein signaling pathways that are tightly linked to dopamine receptors in the brain. Using this approach BetaBlue anticipates being able to to correct the abnormalities in activity of the dopamine pathway in different regions of the brain to benefit people suffering with schizophrenia whilst minimizing off-target therapeutic side effects that are associated with current therapeutics.